Page 1211 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

27. Bath P, Chalmers J, Powers W, et al. International Society of Evaluation Trial (EPITHET): a placebo-controlled randomised
Hypertension (ISH): statement on the management of blood trial. Lancet Neurol. 2008;7:299-309.
pressure in acute stroke. J Hypertens. 2003;21:665-672. 41. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prou-
28. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the rokinase for acute ischemic stroke. The PROACT II study:
early management of adults with ischemic stroke: a guide- a randomized controlled trial. Prolyse in Acute Cerebral
line from the American Heart Association/American Stroke Thromboembolism. JAMA. 1999;282:2003-2011.
Association Stroke Council, Clinical Cardiology Council, 42. Ogawa A, Mori E, Minematsu K, et al. Randomized trial of
Cardiovascular Radiology and Intervention Council, and the intraarterial infusion of urokinase within 6 hours of middle
Atherosclerotic Peripheral Vascular Disease and Quality of cerebral artery stroke: the middle cerebral artery embolism
Care Outcomes in Research Interdisciplinary Working Groups: local fibrinolytic intervention trial (MELT) Japan. Stroke.
the American Academy of Neurology affirms the value of 2007;38:2633-2639.
this guideline as an educational tool for neurologists. Stroke.
2007;38:1655-1711. 43. Powers WJ. Thromobolysis for acute ischemic stroke: is intra-
arterial better than intravenous? A treatment effects model.
29. Robinson TG, Potter JF, Ford GA, et al. Effects of antihyperten- J Stroke Cerebrovasc Dis. 2012;21:401-403.
sive treatment after acute stroke in the Continue or Stop Post-
Stroke Antihypertensives Collaborative Study (COSSACS): a 44. Powers WJ: Intra-arterial therapies for acute ischemic stroke: unsafe
prospective, randomised, open, blinded-endpoint trial. Lancet and without proven value. J Neurointervent Surg. 2012;4:164-166.
Neurol. 2010;9:767-775. 45. Chen ZM, Sandercock P, Pan HC, et al. Indications for early
aspirin use in acute ischemic stroke: a combined analysis of
30. Sandercock PAG, Counsell C, Tseng M-C. Low-molecular-
weight heparins or heparinoids versus standard unfractionated 40 000 randomized patients from the chinese acute stroke trial
heparin for acute ischaemic stroke. Cochrane Database Syst Rev. and the international stroke trial. On behalf of the CAST and
2008:CD000119. IST collaborative groups. Stroke. 2000;31:1240-1249.
46. Swanson RA. Intravenous heparin for acute stroke: what can we
31. Hinchey JA, Shephard T, Furie K, et al. Formal dyspha-
gia screening protocols prevent pneumonia. Stroke. 2005;36: learn from the megatrials? Neurology. 1999;52:1746-1750.
1972-1976. 47. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low
molecular-weight heparin versus aspirin in patients with acute
32. Adams HP, Adams RJ, Brott T, et al. Guidelines for the early
management of patients with ischemic stroke: a scientific ischaemic stroke and atrial fibrillation: a double-blind ran-
statement from the Stroke Council of the American Stroke domised study. HAEST Study Group. Heparin in Acute Embolic
Association. Stroke. 2003;34:1056-1083. Stroke Trial. Lancet. 2000;355:1205-1210.
48. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk
33. The NINDS t-PA Stroke Study Group. Intracerebral hemor-
rhage after intravenous t-PA therapy for ischemic stroke. Stroke. of early death and recurrent stroke and effect of heparin in 3169
1997;28:2109-2118. patients with acute ischemic stroke and atrial fibrillation in the
International Stroke Trial. Stroke. 2001;32:2333-2337.
34. Steiner T, Bluhmki E, Kaste M, et al. The ECASS 3-hour
cohort. Secondary analysis of ECASS data by time stratifica- 49. Antithrombotic Trialists’ Collaboration. Collaborative meta-
tion. ECASS Study Group. European Cooperative Acute Stroke analysis of randomised trials of antiplatelet therapy for preven-
Study. Cerebrovasc Dis. 1998;8:198-203. tion of death, myocardial infarction, and stroke in high risk
patients. BMJ. 2002;324:71-86.
35. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with
early stroke treatment: pooled analysis of ATLANTIS, ECASS, and 50. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive
NINDS rt-PA stroke trials. Lancet. 2004;363:768-774. surgery in malignant infarction of the middle cerebral artery:
a pooled analysis of three randomised controlled trials. Lancet
36. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment Neurol. 2007;6:215-222.
with intravenous alteplase and outcome in stroke: an updated
pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET 51. Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression
trials. Lancet. 2010;375:1695-1703. for space-occupying cerebral infarction (the Hemicraniectomy
After Middle Cerebral Artery infarction with Life-threatening
37. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis Edema Trial [HAMLET]): a multicentre, open, randomised
with recombinant tissue plasminogen activator for acute hemi- trial. The Lancet Neurol. 2009;8:326-333.
spheric stroke. The European Cooperative Acute Stroke Study
(ECASS). JAMA. 1995;274:1017-1025. 52. Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment
in sinus venous thrombosis. Lancet. 1991;338:597-600.
38. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind
placebo-controlled trial of thrombolytic therapy with intrave- 53. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of
nous alteplase in acute ischaemic stroke (ECASS II). Second anticoagulant treatment with low-molecular-weight heparin for
European-Australasian Acute Stroke Study Investigators. cerebral sinus thrombosis. Stroke. 1999;30:484-488.
Lancet. 1998;352:1245-1251. 54. Homma S, Sacco R, Di Tullio M, Sciacca R, Mohr J. Effect of
medical treatment in stroke patients with patent foramen ovale:
39. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP,
Hamilton S. Recombinant tissue-type plasminogen activator patent foramen ovale in Cryptogenic Stroke Study. Circulation.
(Alteplase) for ischemic stroke 3 to 5 hours after symptom 2002;105:2625.
onset. The ATLANTIS Study: a randomized controlled trial. 55. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular
Alteplase Thrombolysis for Acute Noninterventional Therapy events associated with patent foramen ovale, atrial septal aneu-
in Ischemic Stroke. JAMA. 1999;282:2019-2026. rysm, or both. N Engl J Med. 2001;345:1740-1746.
40. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase 56. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery
beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic dissection. Cochrane Database Syst Rev. 2010;10:CD000255.

Section06-O-ref.indd 2 12/10/2014 6:03:38 PM